The discs large-associated protein (DLGAP) family has been implicated in psychological and neurological diseases. However, few studies have explored the association between the expression of DLGAPs and different types of cancer. Therefore, the present study analyzed the status of DLGAPs in gastric cancer (GC) using bioinformatic tools. Analyses of data obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases revealed that there was selective upregulation of DLGAP4 and DLGAP5 expression in GC tissues when compared with normal gastric tissues. In addition, survival analysis using OncoLnc indicated that high expression of DLGAP4 was significantly correlated with shorter overall survival for all GC patients. However, Kaplan-Meier plots demonstrated that the expression of all DLGAPs, except for DLGAP3, was correlated with patient prognosis; DLGAP4 was consistently associated with GC. DLGAP4 mRNA and protein distributions were examined by reverse transcription-quantitative polymerase chain reaction and immunohistochemsitry. Furthermore, its mutation rate and associated biological processes and signaling pathways were assessed in GC with cBioPortal and FunRich analyses. Taken together, these results indicated that DLGAP4 may serve an oncogenic role in GC development and may be a monitoring target for GC prognosis.
Introduction
Gastric cancer (GC) is a highly aggressive disease, with an incidence that is ranked fifth among all types of cancers worldwide in recent years (1, 2) . There are nearly 1,000,000 new cases of GC diagnosed globally each year (3) . The majority of patients succumb to GC due to late recurrence or distant metastasis, and the 5-year survival rate for GC patients is <5% (4) . Thus, there is an urgent requirement to identify biomarkers associated with the prognosis of patients with GC. Although some targets are currently in clinical use, including human epidermal growth factor receptor 2 (5,6), vascular endothelial growth factor receptor-2 (7), excision repair cross complementing gene 1 (8) , B-cell lymphoma 2, and Ki-67 (9) , the heterogeneous nature of GC renders these as only weakly predictive. Therefore, the aim of the present study was to identify novel molecular markers associated with the prognosis of GC.
The discs large-associated protein (DLGAP) family includes five members, namely DLGAP1, 2, 3, 4 and 5, which are distributed on different chromosomes and generate transcript variants of varying lengths (10) . They were originally detected in the rat (11, 12) , and then the structures and functions of their human homologues were described. All DLGAPs share three key domains, including a dynein light chain domain (13) , a 14-amino-acid repeat domain (14) (15) (16) , and a guanylate kinase-associated protein homology domain (17, 18) . These specific regions enable DLGAPs to interact with numerous other proteins, including SH3 and mutiple ankyrin repeat domain protein (19) , DLG4 proteins (14-16), Stargazin proteins (20) (21) (22) (23) and the Homer family proteins (24) . To date, the role of DLGAPs in cancer remains unclear.
Until now, there have been no studies that have investigated the function of DLGAPs in GC. The present study evaluated the expression of DLGAPs in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and investigated the correlation between prognostic significance and the expression of DLGAPs to identify which DLGAPs may be relevant for GC. 
Materials and methods

Identification
Expression of DLGAPs from TCGA and GEO databases.
To assess the expression of DLGAPs in GC, samples were collected from the TCGA and GEO databases. First, the expression of DLGAPs was copmared between NG and GC tissues, and then matched GC and adjacent para-cancer (APC) tissues were also compared and evaluated. (25) and the expression of DLGAP4 was detected using QuantiTect SYBR Green polymerase chain reaction (PCR) kits (Qiagen GmbH, Hilden, Germany) on a Bio-Rad CFX96 system (Bio-Rad Laboratories, Inc, Hercules, CA, USA). β-actin was applied as an internal standard. The thermocycling conditions for reverse transcription-quantitative (RT-q) PCR were as follows: 95˚C for 30 sec, 39 cycles of 5 sec at 95˚C and 30 sec at 58˚C. The expression was calculated using the 2 -ΔΔCq method (26) . The sequences of the primers were as follows: β-actin forward, 5'-CCT TGC ACA TGC CGG AG-3' and reverse, 5'-GCA CAG AGC CTC GCC TT-3'; and DLGAP4 forward, 5'-GCT GTC TCT TTG TCT CTG CCC-3' and reverse, 5'-TGG AAG GTG TTC TCA AGG GG-3'. At the same time, tissues were also fixed in 4% formaldehyde at room temperature for 48 h in preparation for immunohistochemistry (IHC) (27) with rabbit anti-DLGAP4 primary antibody (BIOSS, Beijing, China; cat. no. AE080301) in PBS (1:500) overnight at 4˚C.
Bioinformatics analysis using multiple tools. Proteins coexpressed with DLGAP4 with a Pearson score ≥0.4 in the cBioPortal database (www.cbioportal.org) were selected for examination and their correlation was assessed using Cytoscape software (version 3.6.0; www.cytoscape.org). In addition, all DLGAP4-associated proteins were analyzed for their roles in biological processes and signaling pathways with the Functional Enrichment (FunRich; version: 2.1.2) tool (www.funrich.org).
Statistical analysis. All statistical analyses were performed in SPSS 17.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 5.01 (GraphPad Software, Inc., La Jolla, CA, USA). The expression of DLGAPs among GC, NG and APC tissues in the TCGA and GEO databases were compared with Student's t-tests. In addition, the association between each DLGAP and the prognosis of patients with GC was evaluated with Kaplan-Meier plotter survival curves and OncoLnc survival curves. Experimental data were presented as the mean ± SD and experimental repeats were performed three times. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of DLGAPs in GC.
Comparisons of DLGAP expression data from TCGA database revealed no significant differences in the expression of DLGAP1 (P=0.4522; Fig. 2B ). Similarly, repeating these analyses with GEO data demonstrated no significant differences in the expression of DLGAP1 (P=0.0691; Fig. 3A ) and a significant difference in the expression of DLGAP5 (P=0.0414; Fig. 3B ) between GC (n=22 cases) and NG tissues (n=8 cases). Due to the lack of expression data for DLGAP2 and DLGAP3, the present study was unable to evaluate their expression and perform statistical analysis. In addition, as only two samples were available for DLGAP4, a P-value was not able to be generated (Fig. 3C) .
Expression of DLGAP4 in clinical samples.
RT-qPCR analysis of 19 pairs of clinical samples revealed a similar trend to the above expression results from the TCGA and GEO databases (P<0.0001; Fig. 3D ). IHC demonstrated that DLGAP4 was overexpressed in GC when compared with APC tissues (Fig. 4) .
GC survival analysis in association with DLGAP expression.
The correlation between the expression of DLGAPs and the prognosis of patients with GC was assessed in two different ways. Analysis of the overall survival (OS) of 378 GC patients in OncoLnc (www. oncolnc.org) revealed that high expression of DLGAP4 was correlated with a shorter OS in GC patients (P=0.0465; Fig. 5) . However, the expression of other DLGAP family members was not statistically associated with the prognosis of patients with GC (P=0.115 for DLGAP1l P=0.065 for DLGAP2; P=0.946 for DLGAP3; and P=0.33 for DLGAP5; Fig. 5) .
Evaluation of the prognostic significance of DLGAPs in GC with the Kaplan-Meier plotter, which included four types of cancers, revealed that the expression of all DLGAP family members, except DLGAP3, was correlated with the prognosis of patients with GC (P=5x10 -8 for DLGAP1, P=3.6x10 -7 for DLGAP2; P=0.22 for DLGAP3; P=1.4x10 -9 for DLGAP4; and P=7x10 -11 for DLGAP5; Fig. 6 ).
Bioinformatic analysis of DLGAP4 in GC.
Based on the aforementioned analysis, the present study further investigated the potential DLGAP4-associated molecular mechanisms in the pathogenesis of GC. Analysis of the DLGAP4 variants in GC using data and tools provided by cBioPortal revealed that mutations, including missense mutations, amplification, mRNA Figure 1 . DLGAP status between GC and NG tissues from TCGA database. The results showed that no significant differences were discovered in the expression of (A) DLGAP1, (B) DLGAP2 and (C) DLGAP3. However, (D) DLGAP4 and (E) DLGAP5 were significantly upregulated in GC tissues when compared with NG tissues. DLGAP, discs large-associated protein; GC, gastric cancer; NG, normal gastric. upregulation and truncating mutations, were present in ~9% of GC tissue samples (Fig. 7A) . When the coexpression data obtained from cBioPortal were evaluated, ~20,000 interacting proteins were observed in the DLGAP4 network. The proteins Figure 3 . DLGAP status in GC from the Gene Expression Omnibus database and clinical samples. The results showed no significant difference in the expression of (A) DLGAP1 and a significant difference in the expression of (B) DLGAP5 between GC and normal gastric tissues. Due to the lack of expression data for DLGAP2 and DLGAP3, the present study was unable to evaluate its expression and perform statistical analysis. In addition, as only two samples were available for (C) DLGAP4, a P-value could not be generated. associated with DLGAP4 with a Pearson score ≥0.4 included, A1 α2 repressin protein splicing factor homolog (AAR2), matrix metalloproteinase 24 (MMP24), zinc finger protein 853 (ZNF853), cluster of differentiation 99 molecule like 2 (CD99L2), ZNF358 and ZNF396; the association network, as drawn in Cytoscape software, is presented in Fig. 7B . Finally, the possible biological processes and pathways of DLGAP4 were investigated using FunRich software (Fig. 8) . The major biological processes of DLGAP4 were comprised of 'signal transduction' (15.1%) and 'cell communication' (14.2%). Biological pathways were dominated by 'regulation of RAC1 activity' (3.4%) and 'regulation of p38-α and p38-β' (2.8%).
Discussion
GC is a common gastrointestinal tumor that threatens human health (28) . As there are no typical, clear features of early GC, it is often not diagnosed until the late stages, leading to poor surgery prognosis (29) and a 5-year survival rate of only ~30% (30) . The main cause of postoperative mortality is tumor metastasis or recurrence. Therefore, it is important to identify novel targets for monitoring patient prognosis with the aim of prolonging survival. The cellular biological role of DLGAPs as scaffold proteins suggests that they are able to bind to other substances and therefore, are potenitally involved in cancer progression and tumor metastasis. Until now, DLGAPs, particularly DLGAP1, DLGAP2 and DLGAP3, have been investigated largely in the context of psychological and neurological conditions, including schizophrenia (31), autism spectrum disorder (32), trichotillomania (33) , obsessive compulsive disorder (33) (34) (35) and cerebellar ataxia (36) . The results of the present study indicated that DLGAP4 and DLGAP5 had significantly higher expression levels in GC tissues than in NG tissues, as well as upregulated expression in GC tissues when compared with APC tissues.
In addition, the present evaluation of the assocations between the expression of DLGAPs and the prognosis of patients with GC supported the notion that DLGAPs may serve a role in GC. The analysis of the OncoLnc data (37) demonstrated that there was a significant association between the expression of DLGAP4 and the prognosis of patients with GC. Furthermore, the Kaplan-Meier plotter analysis (38) revealed that the expression of DLGAP1, DLGAP2, DLGAP4 and DLGAP5 were correlated with the prognosis of GC patients. Therefore, DLGAP4, in particular, was strongly implicated as a putative oncogene contributing to GC tumorigenesis. The RT-qPCR and IHC results supported this hypothesis. More mechanistic experiments, in vivo and in vitro, are required to determine whether DLGAP4 serves a causative role in GC.
The present cBioPortal analyses (39, 40) demonstrated that there were GC-associated DLGAP mutations, with missense mutations being the most common type of alteration, followed by amplification, mRNA upregulation and truncating mutations. It was speculated that multiple DLGAP4 mutations may be associated with DLGAP4 protein expression changes. Any mutation that disrupts the CpG island located in the promoter region would have the potential to result in epigenetic changes. Thus, such alterations may facilitate the development of GC by increasing the expression of DLGAP4 transcript variants. Minocherhomji et al (36) obtained evidence that indicated that there was a similar mechanism in the cerebellar ataxia; however, more studies are required to confirm this.
The present gene coexpression analysis with cBioPortal data revealed that the genes that were the most likely to interact with DLGAP4 included AAR2, MMP24, ZNF853, CD99L2, ZNF358 and ZNF396. This result suggested that DLGAP4's involvement in GC may potentially require interactions with other genes. The present examination of biological processes with the FunRich tool (41, 42) revealed that DLGAP4, acting as a transcription factor, can participate in a series of signal pathways, and it was also demonstrated that DLGAP4 can function in a variety of biological processes, including signal transduction and cell communication. This information will be utilized to design our next in-depth study.
In conclusion, based on the present comprehensive analysis, the results of the present study revealed that there was a robust association between DLGAP4 expression and the prognosis of patients with GC. The significant overexpression of DLGAP4 in GC suggests that DLGAP4 may be a promising potential prognostic marker for GC. The actual mechanisms of DLGAP4 in GC remain unknown and require future investigation. The bioinformatic method employed in the present study is a useful tool for predicting and screening new features; however, it lacks mechanistic power. Therefore, further in vitro and in vivo validation is required to assess the role of DLGAP4 in GC. 
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